小核酸药物:全球产业实现多维突破 中国创新药企展现全球竞争力

中信建投证券
Sep 28

核心观点:从商业化角度来说,Amvuttra、Leqvio展现重磅药物潜力,全球龙头公司Alnylam今年将有望实现盈利。从适应症角度来说,25-26年是适应症突破的重要验证期,减重适应症将迎来POC时刻,CNS适应症有望陆续开启探索。从技术角度来说,肝外递送逐步突破。TRiM、AOC等肝外递送方式崭露头角。Avidity研发的AOC药物Del-zota,作为AOC首款药物疗效突出,预计将于...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10